Proteomics International Laboratories (ASX:PIQ) - Managing Director, Dr Richard Lipscombe
Managing Director, Dr Richard Lipscombe
Source: Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Proteomics International Laboratories’ (PIQ) PromarkerD Immunoassay kit has been CE Marked as an in vitro diagnostic medical device
  • PromarkerD forms part of a greater test system used to predict the onset of diabetic kidney disease
  • This is the only test of its kind available for use in the European Union
  • The World Health Organisation estimates there are 60 million adults in Europe living with diabetes
  • Proteomics considers its device to be key in preventing serious complications arising from late stage detection
  • Company shares are up 7.41 per cent and are trading at 29 cents each

Proteomics International Laboratories (PIQ) has secured CE Mark registration for its PromarkerD Immunoassay kit as an in vitro diagnostic (IVD) medical device.

PromarkerD forms part of the PromarkerD test system which is the only test available in the European Union (EU) for early detection of diabetic kidney disease (DKD).

The PromarkerD Immunoassay is the high-throughput version of the PromarkerD Mass Spectrometry (MS) test system which has already received CE Marking. This will allow more labs to process much higher numbers of samples at a cost effective rate.

“With CE Mark the immunoassay offers a higher-throughput option for testing laboratories who want access to our ground-breaking test for predicting diabetic kidney disease – one that could enable earlier therapeutic intervention to minimise the effect of this crippling disease,” Managing Director Dr Richard Lipscombe said.

The World Health Organisation estimates there are 60 million adults with diabetes in Europe, and currently 1 in 3 have chronic kidney disease.

Chronic kidney disease is one of the main and most serious complications arising from diabetes and, if unchecked, can lead to dialysis or a kidney transplant. This is why early detection is crucial in preventing this treatment.

PromarkerD is a simple, low-cost blood test that uses a unique protein ‘fingerprint’ to detect the onset of disease up to four years before clinical symptoms appear.

Achieving CE Mark registration for the PromarkerD provides a strong foundation for it to receive U.S. FDA approval.

Company shares are up 7.41 per cent and are trading at 29 cents each at market close.

PIQ by the numbers
More From The Market Herald

" Creso Pharma (ASX:CPH) signs potential partnership with Gotro for Sierra pet products

Creso Pharma (ASX:CPH) signs a heads of agreement with leading pet care distributor, Gotro Global, to…
The Market Herald Video

" Botanix Pharmaceuticals (ASX:BOT) accelerates Sofpironium Bromide NDA filing

Botanix Pharmaceuticals (ASX:BOT) has accelerated the submission of a New Drug Approval (NDA) for its Sofpironium…
The Market Herald Video

" ResApp (ASX:RAP) extends Medgate licence agreement in line with expansion plans

ResApp Health (ASX:RAP) has agreed to a 12 month extension to its commercial licence agreement with…

" Alterity Therapeutics (ASX:ATH) doses first patient in MSA trial

Alterity Therapeutics (ASX:ATH) doses its first patient in a clinical trial for a rare Parkinsonian disorder.